The Spur Elute medical device is designed to address in-stent restenosis in coronary arteries. Credit: Kateryna Kon / Shutterstock.

Reflow Medical has enrolled the first patient for a pilot study to assess the Coronary Sirolimus-Eluting Retrievable Scaffold System, known as Spur Elute.

The Spur Elute medical device is designed to address in-stent restenosis (ISR) in coronary arteries, a condition that can lead to increased mortality and hospital readmissions.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Titled ‘Drug-eluting coronary spur stent as a primary treatment for in-stent restenosis of the coronary arteries’ (DEEPER CORONARY), the study is set to enrol ten subjects across up to three centres in New Zealand.

The system’s Retrievable Scaffold Therapy (RST) technology works by creating channels that enhance the uptake of antiproliferative drugs and dilate the arterial lumen for optimal procedural gain, after which the device is removed.

Wellington Hospital in New Zealand interventional cardiologist Scott Harding is the principal investigator of the study.

See Also:

Harding said: “It’s exciting to take part in the study of this novel platform, which has the potential to successfully treat patients suffering from in-stent restenosis.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Reflow Medical CEO and co-founder Isa Rizk said: “These enrolments take us one step closer to enabling physicians to utilise the Spur platform for treating patients with cardiovascular disease, and ISR in particular.

“We are so proud of the entire team and grateful to our external CRO, Mobius Medical, for reaching this milestone.”

The pilot study follows Reflow’s introduction of the coraCatheters line last year for complex percutaneous coronary interventions.

Earlier this year, Reflow Medical’s stent system designed to treat de novo or restenotic lesions in the infrapopliteal arteries was awarded a CE mark.